Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.50 |
| ▸ | HRH2 | P25021 | 9/20 | 0.49 |
| ▸ | HRH1 | P35367 | 9/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15163479 | 0.94 | HRH3 (0.44) | HRH3HRH2HRH1KCNH2KDM1A | |
| Hydrochloric Acid SCHEMBL1618281 | 0.94 | HRH3 (0.43) | HRH3HRH2HRH1KCNH2KDM1A | |
| Hydrochloric Acid SCHEMBL3122612 | 0.94 | HRH3 (0.43) | HRH3HRH2HRH1KCNH2KDM1A | |
| SCHEMBL3124752 | 0.85 | KCNH2 (0.48) | HRH3HRH2HRH1KCNH2KDM1A | |
| Hydrochloric Acid SCHEMBL3132895 | 0.84 | KCNH2 (0.47) | HRH3HRH2HRH1KCNH2KDM1A | |
| SCHEMBL4669350 | 0.83 | KCNH2 (0.49) | HRH3HRH2HRH1KCNH2USP30 | |
| SCHEMBL4130153 | 0.83 | KCNH2 (0.51) | HRH3HRH2HRH1KCNH2USP30 | |
| SCHEMBL4133463 | 0.83 | KCNH2 (0.54) | HRH3HRH2HRH1KCNH2USP30 | |
| SCHEMBL1619064 | 0.83 | HRH3 (0.70) | HRH3HRH2HRH1KCNH2MEN1 | |
| SCHEMBL2964313 | 0.82 | HRH3 (0.43) | HRH3HRH2HRH1KCNH2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928225-B2 | Oxabispidine compounds for the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2011-04-19 | — | — | US | disclosed |
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| EP-1893619-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTMIAS | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006135316-A1 | New oxabispidine compounds for the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | RYR1, KCNH1, CACNA1E | HRH3 448/4885HRH2 521/4885HRH1 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.